JOHNSON & JOHNSON — Director's Dealing 2023

May 2, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2023-05-01

Reporting Person: REED JOHN C (EVP, Pharmaceuticals R&D)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-01	Restricted Share Units	$	A	75765.0000	Acquired		Common Stock (75765.0000)	Direct

Footnotes

F1: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to acquire one share of Common Stock.

F2: The Restricted Share Units vest in three equal annual installments beginning on the first anniversary of the grant date.